Adtalem Shares Plummet Amid Fraud Probe Despite Record Performance

Adtalem Global Education finds itself in a perplexing market scenario where exceptional operational achievements clash with severe legal uncertainties. The education provider’s stock has experienced a dramatic selloff following the announcement of a fraud investigation, creating a stark contrast between its financial health and investor sentiment.

Stellar Quarterly Results Exceed Projections

The company’s first quarter 2026 financial performance demonstrated remarkable strength. Adjusted earnings per share reached $1.75, substantially outperforming analyst expectations of $1.57 and representing a 35.7% year-over-year increase. Revenue climbed to $462.3 million, exceeding forecasts by 10.8%.

Enrollment metrics further underscored this positive trajectory:
– Total student population: 97,359 (8.0% growth)
– Chamberlain University: 11th consecutive quarter of expansion (2.2% increase)
– Walden University: Record enrollment levels (13.6% surge)
– Medical & Veterinary segment: Third successive growth quarter (2.4% rise)

Management Confidence Through Share Repurchases

Adtalem’s leadership has projected continued optimism through forward guidance. For the full 2026 fiscal year, the company anticipates revenue between $1.900 billion and $1.940 billion, translating to growth of 6.0% to 8.5%. Adjusted earnings per share are forecast to reach $7.60 to $7.90, representing a 14.0% to 18.5% improvement.

Demonstrating confidence in the company’s valuation, management accelerated its $150 million share repurchase program on November 5, 2025. With $136 million remaining in the authorization, this move signals strong belief in the company’s long-term prospects.

Should investors sell immediately? Or is it worth buying Adtalem Global Education?

Fraud Investigation Triggers Market Panic

Despite these robust fundamentals, investor confidence was severely shaken when a law firm initiated a securities fraud investigation on November 9, 2025. The probe examines potential misrepresentations concerning student enrollment figures and regulatory compliance. Particular scrutiny has fallen on Chamberlain University’s decelerating growth momentum.

Historic Market Reaction Defies Fundamentals

The market response has been severe and swift. After closing at $141.77 on October 30 following the earnings release, the stock collapsed by 30.86% the next day to $98.02. The decline continued through November 7, with shares falling to $94.89.

From a technical perspective, the security appears extremely oversold with an RSI reading of just 11. The price-to-earnings ratio of 13.81 approaches historical lows, raising questions about whether these valuation metrics adequately compensate for the legal risks.

Key Data Points:
– Q1 EPS: $1.75 (exceeded expectations)
– Q1 Revenue: $462.3 million (10.8% above projections)
– Annual Forecast: $1.900-$1.940 billion revenue
– Fraud Investigation: Commenced November 9, 2025
– Single-Day Decline: Exceeded 30%
– Institutional Ownership: 98.84%

The dramatic selloff illustrates how legal uncertainties can overshadow operational excellence in market valuation. With institutional investors dominating the shareholder base, the central question remains when rational valuation might resurface amid the ongoing investigation.